Literature DB >> 3709643

Isosorbide dinitrate in plasma and dialysate during haemodialysis.

H Bauer, H Laufen, H E Franz.   

Abstract

In 10 patients with end stage renal disease on regular haemodialysis the plasma concentrations and dialyzer clearance of isosorbide dinitrate (ISDN) were determined after an oral dose of a retarded release formulation of 60 mg ISDN. The maximal plasma concentration of ISDN 2-7 h after oral administration was higher (14 ng/ml) than has been reported in healthy volunteers. The haemodialyzer clearance of ISDN was 92.4 ml/min at a blood flow of 200 ml/min and dialysate flow of 500 ml/min. During a 5-h haemodialysis an average of 0.3 mg ISDN was removed from the patient's circulation, representing about 0.5% of the administered dose and about 3% of the available drug in the circulation. No influence of haemodialysis on the plasma level of ISDN was found.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709643     DOI: 10.1007/bf00614300

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  [Pharmacokinetics and metabolism of organic nitrates].

Authors:  H Steudel
Journal:  Z Kardiol       Date:  1985

2.  Isosorbide dinitrate pharmacokinetics.

Authors:  T Taylor; L F Chasseaud; E Doyle; R Bonn; A Darragh; R F Lambe
Journal:  Arzneimittelforschung       Date:  1982

3.  [Pharmacokinetics, effect and tolerance of isosorbide dinitrate and isosorbide-5-mononitrate in healthy persons].

Authors:  U Abshagen; S Spörl-Radun; G Betzien; B Kaufmann; R Endele
Journal:  Med Welt       Date:  1981-04-07

4.  Kinetics of isosorbide dinitrate and relationships to pharmacological effects.

Authors:  H L Fung; E F McNiff; D Ruggirello; A Darke; U Thadani; J O Parker
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

5.  [Orally active vasodilators in the management of chronic treatment-resistant cardiac failure (author's transl)].

Authors:  A Wirtzfeld; G Klein; F C Himmler; G Schmidt; I Kutschera; E Sauer
Journal:  Dtsch Med Wochenschr       Date:  1980-10-03       Impact factor: 0.628

6.  Improved method for the rapid determination of isosorbide dinitrate in human plasma and its application in pharmacokinetic studies.

Authors:  H Laufen; F Scharpf; G Bartsch
Journal:  J Chromatogr       Date:  1978-11-01

7.  Fate of isosorbide dinitrate and mononitrates in patients with renal failure.

Authors:  M G Bogaert; M T Rosseel; J Boelaert; R Daneels
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

8.  Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man.

Authors:  H Laufen; M Aumann; M Leitold
Journal:  Arzneimittelforschung       Date:  1983

9.  Use of isosorbide dinitrate saliva concentrations for biopharmaceutical investigations.

Authors:  H Laufen; M Schmid; M Leitold
Journal:  J Pharm Sci       Date:  1983-05       Impact factor: 3.534

  9 in total
  3 in total

Review 1.  Clinical pharmacokinetics of nitrates.

Authors:  M G Bogaert
Journal:  Cardiovasc Drugs Ther       Date:  1994-10       Impact factor: 3.727

2.  Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage.

Authors:  J Evers; R Bonn; A Boertz; W Cawello; H A Dickmans; M Weiss
Journal:  Klin Wochenschr       Date:  1989-03-15

Review 3.  Clinical pharmacokinetics of vasodilators. Part II.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.